Leqembi Safety: Label Has Distinct MRI Schedule But Follows Aduhelm On ARIA Management

With the second amyloid-targeting antibody for treatment of Alzheimer’s, US FDA opted for a class-wide approach to management of amyloid-related imaging abnormalities, but with a product-specific MRI monitoring schedule that differs from that of Aduhelm.